global
Variables
Utilities
CUSTOM STYLES

FDA Grants Nelkarmi (neladalkib) Accelerated Approval for ALK-Positive NSCLC

November 18, 2026

Did you know? ALK is a gene found in cells that’s normally only active before birth. In some people, the ALK gene joins or fuses with a different gene. This causes the ALK gene to become active again and cells to begin growing out of control, causing cancer. ALK fusions occur in about 5 out of every 100 cases (5%) of non-small cell lung cancer (NSCLC).

On November17, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Nelkarmi (neladalkib) for people with locally advanced (cancer that has spread to nearby tissues or lymph nodes) or metastatic (cancer that has spread to other parts of the body) ALK-positive NSCLC who have already been treated with:

  • An ALK-targeting tyrosine kinase inhibitor (TKI) called Alecensa (alectinib), OR
  • 2 or more ALK-targeting TKIs and platinum-based chemotherapy.

Nelkarmi (neladalkib) is a type of targeted therapy called a kinase inhibitor. It blocks the abnormal ALK protein that helps cancer cells grow. It is taken by mouth once a day, at the same time each day, with or without food.

This approval is based on the results of the ALKOVE-1 study, which looked at how safe and effective Nelkarmi (neladalkib) is for adults with locally advanced or metastatic ALK-positive NSCLC who had already received Alecensa (alectinib) for metastatic treatment OR 2 or more ALK-targeting TKIs and platinum-based chemotherapy. Researchers looked at the response rate (percentage of people whose tumors shrank or went away) and how long those responses lasted. Results showed:

  • About 49 out of 100 people (49%) who had received Alecensa (alectinib) as their only previous therapy had a response to Nelkarmi (neladalkib). Among those who responded, 76% had a response that lasted 6 months or longer, and 52% had a response that lasted 1 year or longer.
  • About 32 out of 100 people (32%) who had received ALK-targeting TKIs and platinum-based chemotherapy had a response to Nelkarmi (neladalkib). Among those who responded, 69% had a response that lasted 6 months or longer, and 51% had a response that lasted 1 year or longer.

This is an exciting update from the FDA because it gives people with ALK-positive NSCLC who have already been treated with an ALK-targeted therapies another treatment option.

Please speak with your healthcare team for more information about Nelkarmi (neladalkib) and to see if it may be an option for you. If you have questions about treatment, trials, or biomarker testing, contact our LungMATCH team at support@go2.org or 1-800-298-2436.  

Read the full FDA announcement.